A kind of ticagrelor orally disintegrating tablet and preparation method thereof
Oral disintegration tablets were prepared by mixing ticagrelor with cheap auxiliary materials such as sodium carboxymethyl starch, povidone, mannitol and xylitol, which solved the bioavailability of ticagrelor tablets in low-soluble environments. The problem of low achieves rapid disintegration and high dissolution, is suitable for industrial production and reduces costs.
Patent Information
- Application Number
- CN202310173481.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-28
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-02-28
AI Technical Summary
Existing ticagrelor tablets are difficult to dissolve rapidly in low solubility and low permeability environments, resulting in low bioavailability and complex preparation process and not suitable for large-scale industrial production.
Oral disintegration tablets are prepared by using a simple mixing direct tableting process, ticagrelor is mixed with cheap auxiliary materials such as croscarmellomethyl starch, povidone, mannitol and xylitol, to simplify production operations and improve disintegration performance. .
The ticagrelor tablets have been quickly disintegrated within 1 minute, with dissolution reaching more than 90%, bioavailability is improved, and the process is stable and cost is reduced, making them suitable for industrial production.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of oral solid preparations, and in particular to a method for preparing a ticagrelor orally disintegrating tablet. Background Art
[0002] With the increase in the average human lifespan and the decline in swallowing ability with aging, oral tablet administration has become a concern. It is estimated that about 50% of people have difficulty swallowing tablets and capsules, which affects compliance with drug treatment. In the field of pediatrics and geriatrics, there is a great demand for solid preparations that can be dissolved or suspended in water, chewed, or quickly dissolved in the mouth. Oral rapid dispersible preparations (Orally disintegrating tablets, referred to as ODT) that can be quickly dispersed or dissolved without water and swallowing can solve this problem. This dosage form can be quickly dispersed or dissolved in saliva after being placed in the mouth, and the drug can be absorbed through the mucous membrane in the mouth or esophagus. The bioavailability is higher than that of ordinary preparations, and the side effects caused by first-pass metabolism can also be reduced.
[0003] The present invention discloses a method for preparing a ticagrelor orally disintegrating tablet, wherein the active ingredient is ticagrelor, the English name of which is Ticagrelor, the chemical name of which is (1S, 2S, 3R, 5S)-3-[7-[[(1R, 2S)-2-(3, 4-difluorophenyl)cyclopropyl]amino]-5-propylthiotriazolo[4, 5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1, 2-cyclopentanediol, and the molecular formula of which is C 23 H 28 F2N6O4S, molecular weight is 522.568, chemical structure is:
[0004]
[0005] Ticagrelor belongs to the cyclopentyltriazolopyrimidine class of compounds. It is the first reversible P2Y12 platelet inhibitor and a new type of antiplatelet aggregation drug. It is used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction), including those receiving drug therapy and percutaneous coronary intervention (PCI).
[0006] Ticagrelor tablets were developed by AstraZeneca AB and approved by EMA in 2010. The trade name is Brilique, the dosage form is tablets, and the specifications are 60mg and 90mg. On July 20, 2011, the US FDA approved the listing of the product under the trade name BRILINTA, the dosage form is tablets, and the specification is 90mg. On May 25, 2017, the European Commission approved the listing of AstraZeneca's new formulation of Ticagrelor orally disintegrating tablets (trade name: Brilique, specification: 90mg). Subsequently, Ticagrelor orally disintegrating tablets were listed in 28 EU member states, Ireland, Norway and Liechtenstein.
[0007] Ticagrelor orally disintegrating tablets have been very popular since their launch, helping to address the needs of patients who cannot swallow tablets and can quickly give them medication when they need it. This new formulation provides healthcare professionals with greater flexibility to provide patients with the treatment they need and meet their needs. Ticagrelor orally disintegrating tablets are placed under the tongue when taking the medicine, so that it can quickly dissolve in the saliva. The medicine is then swallowed with or without water. The tablets can also be dissolved in water and used through a nasogastric tube. If patients are intubated or have difficulty swallowing film-coated tablets, they will be able to replace the same strength of Ticagrelor film-coated tablets with Ticagrelor orally disintegrating tablets. However, Ticagrelor is rapidly absorbed after oral administration, with an average T max About 1.5 hours; the average absolute bioavailability is low, only about 36%. According to the BCS classification, ticagrelor belongs to Class IV (i.e., low solubility and low permeability). Its solubility in the physiological pH environment between pH 1.0 and pH 7.4 is about 10µg / ml, and its permeability is about 51%. Since ticagrelor is a low-solubility and low-permeability drug, the dissolution and permeability of its preparations affect the key rate-limiting process of ticagrelor's absorption in the body, which brings huge challenges to pharmaceutical companies.
[0008] Patent CN109700773A and Patent CN109718218A prepare ticagrelor tablets by spray drying technology and solid dispersion technology respectively, which solve the problem of poor solubility of ticagrelor; however, the preparation method is complicated and not suitable for large-scale industrial production.
[0009] Patent CN111450067A discloses a dispersible tablet of ticagrelor and a preparation method thereof. The dispersible tablet is based on ticagrelor as the main drug. Ticagrelor and hydrophilic excipients are co-pulped to a particle size of 30 μm to 60 μm and prepared by direct tablet compression. Although the dispersible tablet disintegrates quickly and the solubility is greater than 85% in 30 minutes, the direct tablet compression process has high requirements for excipients. It is necessary to select direct compression excipients with good adhesion and fluidity, which are expensive.
[0010] Patent CN107530288A discloses an orally disintegrating tablet, the preparation method of which is to first prepare drug-containing particles with active ingredients and excipients, and then mix and compress them with a disintegrating excipient premix, and the tablet has a disintegration time of less than about 60 seconds. However, the disintegrating excipient premix used in the patent is prepared by a co-spray drying method, which is complex and time-consuming, and the market price of the disintegrating excipient premix is several times that of commonly used excipients. If the disintegrating excipient is purchased for large-scale industrial production, the cost of pharmaceutical companies will be greatly increased. Summary of the invention
[0011] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a new orally disintegrating tablet and a preparation method thereof. The present invention adopts a simple mixed direct tableting process to mix the active ingredient with the orally disintegrating granules and lubricants for tableting, thereby simplifying the drug production operation; after a large number of experimental comparisons, the present invention only uses four inexpensive commonly used excipients, namely, cross-linked carboxymethyl starch sodium, povidone, mannitol and xylitol, to prepare orally disintegrating granules with good uniformity, strong disintegration performance and good fluidity, which greatly reduces the cost of drug production and effectively ensures the in vivo bioavailability of the active ingredient. The orally disintegrating tablet prepared by the present invention can disintegrate rapidly within 1 minute, has an excellent dissolution effect, and the dissolution rate can reach more than 90% in 5 minutes; it also meets the conditions of acceleration and long-term conditions, and there is no significant change in the related substances during the 6-month placement process.
[0012] To achieve the above object, the present invention provides the following technical solutions:
[0013] A ticagrelor orally disintegrating tablet, characterized in that the active ingredient is mixed with orally disintegrating granules and a lubricant and compressed into tablets, wherein each 1000 tablets are composed of the following weight ratio: 60-90 g of active ingredient, 207-290 g of orally disintegrating granules, and 2-8 g of lubricant; the active ingredient is ticagrelor;
[0014] The orally disintegrating granules are composed of four ingredients selected from cross-linked sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, povidone, lactose, microcrystalline cellulose, cross-linked povidone, hydroxypropyl cellulose, hypromellose, mannitol, xylitol, sucrose, and anhydrous calcium hydrogen phosphate, with a ratio of 30 to 80: 1 to 8: 100 to 150: 4 to 20; one preferred ingredient is cross-linked sodium carboxymethyl starch, povidone, mannitol and xylitol; another preferred ingredient is low-substituted hydroxypropyl cellulose, povidone, anhydrous calcium hydrogen phosphate and xylitol; another preferred ingredient is cross-linked povidone, hypromellose, microcrystalline cellulose and xylitol; another preferred ingredient is a combination of cross-linked povidone, povidone, mannitol and xylitol;
[0015] The lubricant is selected from talc, colloidal silicon dioxide, silicon dioxide, magnesium stearate, stearic acid, and sodium stearyl fumarate.
[0016] The preparation method of the orally disintegrating tablet comprises the following steps:
[0017] Step 1: crush the active ingredient through a 100-200 mesh sieve;
[0018] Step 2: Mixing the active ingredient treated in step 1, the orally disintegrating granules and the lubricant together for 5 to 30 minutes;
[0019] Step 3: Tablet pressing, control the tablet hardness to 4-10kg.
[0020] Through a large number of experimental screenings, the composition of the orally disintegrating granules is further optimized to include cross-linked sodium carboxymethyl starch, povidone, mannitol, and xylitol, with a ratio of 56:2:139:10.
[0021] The preparation method of the orally disintegrating tablet comprises the following steps:
[0022] Step 1: crush the active ingredient through a 200 mesh sieve;
[0023] Step 2: Mix the components of the orally disintegrating granules and wet granulate them, dry the obtained wet granules at 60° C., and sieve the granules with a 30-mesh screen to obtain the orally disintegrating granules;
[0024] Step 3: Mixing the active ingredient treated in step 1, the orally disintegrating granules prepared in step 2 and the lubricant together for 10 minutes;
[0025] Step 4: Tablet pressing, control the tablet hardness to 5-7kg.
[0026] The present invention further discloses the use of the ticagrelor orally disintegrating tablet for improving bioavailability. Experimental results show that the ticagrelor orally disintegrating tablet rapidly disintegrates within 1 minute, has an excellent dissolution effect, and the dissolution rate can reach more than 90% in 5 minutes; there is no significant change in related substances during the 6-month storage process under accelerated conditions and long-term conditions.
[0027] Typical examples of the ticagrelor orally disintegrating tablets disclosed in the present invention are as follows:
[0028] Ticagrelor orally disintegrating tablets are prepared by mixing ticagrelor with orally disintegrating granules and a lubricant and pressing them into tablets, wherein each 1,000 tablets are composed of the following weight ratio: 90 g of ticagrelor, 207 g of orally disintegrating granules, and 3 g of sodium stearyl fumarate; the ingredients in the orally disintegrating granules include cross-linked sodium carboxymethyl starch, povidone, mannitol, and xylitol, with the proportions being 56:2:139:10.
[0029] The preparation method of the ticagrelor orally disintegrating tablet comprises the following steps:
[0030] 1. Grind Ticagrelor through a 200-mesh sieve;
[0031] 2. Add cross-linked sodium carboxymethyl starch, povidone K30, mannitol and xylitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 30-mesh screen to obtain orally disintegrating granules;
[0032] 3. Mix the orally disintegrating granules, crushed ticagrelor and sodium stearyl fumarate in a three-dimensional mixer for 10 minutes;
[0033] 4. Use Φ9.0mm shallow concave round punch to press the tablets and control the tablet hardness to 5-7kg.
[0034] The present invention discloses for the first time a method for preparing an orally disintegrating tablet. Compared with the prior art, the method has the advantages of rapid disintegration, stable quality and high in vivo bioavailability (the bioavailability of the preparation produced in Example 1 and the commercially available preparation were compared by administering the preparation to Beagle dogs, indicating that the ticagrelor dispersible tablets in Example 1 have a fast absorption rate, which is shown as T max The commercial preparation T max 55 minutes; the relative bioavailability of the ticagrelor dispersible tablets produced in Example 1 is improved compared with the commercially available preparation (107.2-90.4) / 90.4=18.6%); in addition, the preparation method of the present invention is easy to industrialize and greatly reduces the production cost.
[0035] The orally disintegrating tablet of the present invention obtained by adopting the above technical solution can ideally produce the purpose and technical effect to be achieved by the present invention. Specifically, the orally disintegrating tablet and the preparation method thereof of the present invention can produce:
[0036] (1) Rapid disintegration, excellent dissolution effect, and high bioavailability;
[0037] (2) The process is stable and the quality reproducibility is strong, which reduces production costs and improves economic benefits.
[0038] It should be noted that, in order to enable persons skilled in the art to more clearly understand the content and technical connotation of the present invention, the inventors of the present invention provide the following explanations of the professional terms, symbols, reagents, consumables and instruments involved:
[0039] “Day 0”: refers to the time when sample preparation is completed;
[0040] "Long-term conditions": refers to a temperature of 30°C ± 2°C and a relative humidity of 65% ± 5%;
[0041] "Accelerated conditions": refers to temperature 40℃±2℃, relative humidity 75%±5%;
[0042] “T max ”: refers to the time when the drug reaches the maximum blood concentration after administration;
[0043] “C max ”: refers to the maximum blood drug concentration detected in the body after administration;
[0044] “AUC 0~∞ ”: refers to the area under the blood drug concentration-time curve. In the process of bioavailability study, for the same dosage, a high value indicates high bioavailability, and a low value indicates low bioavailability. DETAILED DESCRIPTION
[0045] The present invention is described below through specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material components and dosages in these embodiments, without departing from the essence and scope of the present invention, also fall within the scope of protection of the present invention. The raw materials and reagents used in the present invention are all commercially available. In order to facilitate the understanding of the present invention by those skilled in the art to which the present invention belongs, the present invention provides the following specific embodiments to further illustrate the orally disintegrating tablet and its preparation method:
[0046] Example 1
[0047] Prescription (1000 tablets)
[0048]
[0049] Preparation method:
[0050] 1. Grind Ticagrelor through a 200-mesh sieve;
[0051] 2. Add cross-linked sodium carboxymethyl starch, povidone K30, mannitol and xylitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 30-mesh screen to obtain orally disintegrating granules;
[0052] 3. Mix the orally disintegrating granules, crushed ticagrelor and sodium stearyl fumarate in a three-dimensional mixer for 10 minutes;
[0053] 4. Use Φ9.0mm shallow concave round punch to press the tablets and control the tablet hardness to 5-7kg.
[0054] Example 2
[0055] Prescription (1000 tablets)
[0056]
[0057] Preparation method:
[0058] 1. Grind Ticagrelor through a 150-mesh sieve;
[0059] 2. Add low-substituted hydroxypropyl cellulose LH-21, povidone K30, anhydrous calcium hydrogen phosphate and xylitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 30-mesh screen to obtain orally disintegrating granules;
[0060] 3. Mix the orally disintegrating granules, crushed ticagrelor and sodium stearyl fumarate in a three-dimensional mixer for 10 minutes;
[0061] 4. Use Φ9.0mm shallow concave round punch to press the tablets and control the tablet hardness to 5-7kg.
[0062] Example 3
[0063] Prescription (1000 tablets)
[0064]
[0065] Preparation method:
[0066] 1. Grind Ticagrelor through a 200-mesh sieve;
[0067] 2. Add cross-linked polyvinylpyrrolidone XL-10, hypromellose E5LV, microcrystalline cellulose PH101 and xylitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 30-mesh screen to obtain orally disintegrating granules;
[0068] 3. Mix the orally disintegrating granules, crushed ticagrelor and sodium stearyl fumarate in a three-dimensional mixer for 15 minutes;
[0069] 4. Use Φ9.0mm shallow concave round punch to press the tablets and control the tablet hardness to 6-8kg.
[0070] Example 4
[0071] Prescription (1000 tablets)
[0072]
[0073] Preparation method:
[0074] 1. Grind Ticagrelor through a 200-mesh sieve;
[0075] 2. Add cross-linked polyvinylpolypyrrolidone XL-10, polyvinylpolypyrrolidone K30, mannitol and xylitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 24-mesh screen to obtain orally disintegrating granules;
[0076] 3. Mix the orally disintegrating granules, crushed ticagrelor and sodium stearyl fumarate in a three-dimensional mixer for 10 minutes;
[0077] 4. Use Φ9.0mm shallow concave round punch to press the tablets and control the tablet hardness to 5-7kg.
[0078] Comparative Example 1
[0079] Prescription (1000 tablets)
[0080]
[0081] Preparation method:
[0082] 1. Grind Ticagrelor through a 200-mesh sieve;
[0083] 2. Add the crushed ticagrelor, cross-linked sodium carboxymethyl starch, hypromellose E5LV and mannitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 30-mesh screen to obtain drug-containing granules;
[0084] 3. Add cross-linked carboxymethyl starch sodium, povidone K30, mannitol and xylitol into a wet granulator, set the stirring speed to 400 rpm, the cutting speed to 1500 rpm, and mix for 10 minutes; spray purified water for granulation for 1 minute; dry the obtained wet granules in a fluidized bed at 60°C for 15 minutes, and after drying, sieve the granules with a 30-mesh screen to obtain orally disintegrating granules;
[0085] 4. Mix the orally disintegrating granules, drug-containing granules and sodium stearyl fumarate in a three-dimensional mixer for 10 minutes;
[0086] 5. Use Φ10.0mm shallow concave round punch to press the tablets and control the tablet hardness to 5-7kg.
[0087] Test Example 1
[0088] Content uniformity check:
[0089] According to the content uniformity inspection method under the relevant items in the current "Chinese Pharmacopoeia", the content uniformity of Examples 1 to 4, Comparative Example 1 and commercially available preparations was inspected, and the results are as follows:
[0090]
[0091] The content uniformity under the relevant items in the current "Chinese Pharmacopoeia" stipulates that A+2.2S should be ≤15.0; the content uniformity A+2.2S of the samples in Examples 1 to 4 is less than 15.0, which has better content uniformity.
[0092] Test Example 2
[0093] Disintegration time determination:
[0094] According to the disintegration time limit inspection method under the relevant items in the current "Chinese Pharmacopoeia", the disintegration time of Examples 1 to 4, Comparative Example 1 and the commercially available preparations was tested, and 6 tablets were tested for each. The results are as follows:
[0095]
[0096] The current disintegration time limit under the relevant items in the "Chinese Pharmacopoeia" stipulates that all disintegration should be completed within 1 minute; the sample in Example 1 completely disintegrated within 40 seconds, with the fastest disintegration speed. The disintegration time of Examples 1 to 4 is significantly faster than that of Comparative Example 1 and commercially available preparations, and has an excellent rapid disintegration effect.
[0097] Test Example 3
[0098] Dissolution test:
[0099] According to the dissolution test method under the relevant items in the current "Chinese Pharmacopoeia", the test was carried out and the results are as follows:
[0100]
[0101] The current dissolution regulations under the relevant items in the "Chinese Pharmacopoeia" stipulate that the dissolution rate in 15 minutes should not be less than 75%; the dissolution rate of the sample in Example 1 of the present invention in 15 minutes is higher than 90%, which is significantly higher than that of Comparative Example 1 and commercially available preparations, and has excellent dissolution effect.
[0102] Test Example 4
[0103] Related material inspection:
[0104] Example 1 was packaged as sold in the market, and placed under long-term conditions and accelerated conditions together with the commercial preparations. After 6 months, the samples were taken out and tested for related substances. The related substances in Example 1 and the commercial preparations were tested according to the related substance testing methods under the relevant items in the current Chinese Pharmacopoeia. The results are as follows:
[0105]
[0106] The results of the relevant substance inspection show that: after 6 months under long-term conditions and accelerated conditions, the content of the maximum single impurity and total impurities in the relevant substances of the sample of Example 1 is significantly lower than that of the commercially available preparation, and the increase in the content of each impurity is small; this shows that the preparation method in this patent can obtain samples with good levels of relevant substances and high stability.
[0107] Test Example 5
[0108] Beagle dogs were selected as test animals to study the bioavailability of Example 1 of the present invention and the commercially available preparations. It should be noted in advance that during the implementation of the following test scheme, the Beagle dogs were fed with the same standardized diet throughout the entire period to eliminate the possible adverse effects of food on the results.
[0109] Selection and grouping of experimental animals: Female, healthy Beagle dogs of the same age, weighing within the range of 12±1.0kg, a total of 12 dogs were randomly divided into 2 groups, 6 dogs in each group.
[0110] Experimental plan: 1) No drugs were administered 21 days before the experiment; 2) 7 days before the experiment, 1 mg of ticagrelor / kg body weight was administered daily to pre-saturate the background of each test animal, so that the background ticagrelor concentration of each test animal reached a steady-state level; 3) The test animals in each group began to fast at 20:00 one day before the experiment, and 2.4 mg of ticagrelor / kg body weight was administered on an empty stomach at 7:00 on the day of the experiment, and at each sampling time point (0 o'clock, 15 minutes, 30 minutes, 45 minutes, 1.0 hours, 1.5 hours, 2.0 hours, 4.0 hours, 6.0 hours, 8.0 hours, 12.0 hours, 24.0 hours, 48.0 hours), 2 mL of blood was drawn from the median vein of the forelimb for sampling; 4) the Beagle dog ticagrelor ELISA kit was used to detect the ticagrelor content in the samples of each test group of animals at each sampling time point, and the mean of each evaluation item of the 3 Beagle dogs in each test group was calculated. It should be pointed out here that before the sample analysis and detection, the inventors of the present invention conducted a systematic methodological verification of the precision, recovery rate, specificity, detection limit, etc. of this method, and the results showed that the analysis method is scientific and feasible.
[0111] The results of the Beagle dog bioavailability study conducted using the test examples of the present invention are shown in the following table:
[0112]
[0113] According to the above results, the ticagrelor solid preparation and the preparation method thereof of Example 1 obtained by the ticagrelor dispersible tablets have a fast absorption rate, which is shown as T max 45 minutes, while the commercial preparation T max is 55 minutes; the relative bioavailability of ticagrelor in the ticagrelor dispersible tablets of the present invention is increased by (107.2-90.4) / 90.4=18.6% compared with the commercially available preparations, and has a higher bioavailability in the body.
[0114] The above embodiments are only used to help understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. A ticagrelor orally disintegrating tablet, characterized in that The active ingredient is mixed with orally disintegrating granules and a lubricant and compressed into tablets, wherein each 1000 tablets are composed of the following weight ratio: 60-90 g of active ingredient, 207-290 g of orally disintegrating granules, and 2-8 g of lubricant; the active ingredient is ticagrelor; The ingredients of the orally disintegrating granules are cross-linked sodium carboxymethyl starch, povidone, mannitol, and xylitol, with a ratio of 56:2:139:10, and the lubricant is sodium stearyl fumarate; The preparation method of the orally disintegrating tablet is carried out according to the following steps: Step 1: crush the active ingredient through a 100-200 mesh sieve; Step 2: Mix the components of the orally disintegrating granules and wet granulate them, dry the obtained wet granules at 60° C., and sieve the granules with a 30-mesh screen to obtain the orally disintegrating granules; Step 3: Mixing the active ingredient treated in step 1, the orally disintegrating granules prepared in step 2, and the lubricant for 5 to 30 minutes; Step 4: Tablet pressing, control the tablet hardness to 4-10kg.
2. The orally disintegrating tablet according to claim 1, wherein the preparation method comprises the following steps: Step 1: crush the active ingredient through a 200-mesh sieve; Step 2: Mix the components of the orally disintegrating granules and wet granulate them, dry the obtained wet granules at 60° C., and sieve the granules with a 30-mesh screen to obtain the orally disintegrating granules; Step 3: Mixing the active ingredient treated in step 1, the orally disintegrating granules prepared in step 2 and the lubricant for 10 minutes; Step 4: Tablet pressing, control the tablet hardness to 5-7kg.
